There were no clinical trials targeting this result. From the linked article: > Did the 56 Work Lead to Clinical Trials? > [snip] And the answer is that no, I

There were no clinical trials targeting this result. From the linked article: > Did the 56 Work Lead to Clinical Trials? > [snip] And the answer is that no, I have been unable to find a clinical trial that specifically targeted the AB56 oligomer itself It was industry (well short traders) that led to this being uncovered: > He was originally hired by two other neuroscientists who also sell biopharma stocks short - my kind of people, to be honest - to investigate published research related to Cassava Sciences and their drug Simufilam, and that work led him deeper into the amyloid literature.